Capital Research Global Investors Buys 321,262 Shares of Biohaven Ltd. $BHVN

Capital Research Global Investors boosted its stake in Biohaven Ltd. (NYSE:BHVN) by 31.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 1,332,792 shares of the company’s stock after purchasing an additional 321,262 shares during the quarter. Capital Research Global Investors’ holdings in Biohaven were worth $15,047,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. WINTON GROUP Ltd boosted its holdings in Biohaven by 136.3% in the fourth quarter. WINTON GROUP Ltd now owns 64,028 shares of the company’s stock valued at $723,000 after acquiring an additional 36,929 shares in the last quarter. TD Asset Management Inc boosted its holdings in shares of Biohaven by 4.2% during the 4th quarter. TD Asset Management Inc now owns 141,678 shares of the company’s stock valued at $1,600,000 after buying an additional 5,650 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Biohaven by 148.2% during the 4th quarter. BNP Paribas Financial Markets now owns 2,093,816 shares of the company’s stock valued at $23,639,000 after buying an additional 1,250,252 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Biohaven by 145.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 9,152 shares of the company’s stock valued at $103,000 after buying an additional 5,417 shares in the last quarter. Finally, Intech Investment Management LLC boosted its holdings in shares of Biohaven by 14.5% during the 4th quarter. Intech Investment Management LLC now owns 67,096 shares of the company’s stock valued at $758,000 after buying an additional 8,521 shares in the last quarter. Institutional investors own 88.78% of the company’s stock.

Biohaven Price Performance

Shares of NYSE:BHVN opened at $11.11 on Wednesday. Biohaven Ltd. has a fifty-two week low of $7.48 and a fifty-two week high of $18.57. The business has a 50-day simple moving average of $9.84 and a two-hundred day simple moving average of $10.47. The company has a debt-to-equity ratio of 1.87, a quick ratio of 7.41 and a current ratio of 7.41. The firm has a market cap of $1.67 billion, a price-to-earnings ratio of -1.96 and a beta of 1.35.

Biohaven (NYSE:BHVN) last issued its earnings results on Monday, May 4th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.02). On average, analysts expect that Biohaven Ltd. will post -3.07 earnings per share for the current year.

Analyst Upgrades and Downgrades

BHVN has been the topic of a number of research reports. Morgan Stanley dropped their target price on shares of Biohaven from $21.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday, May 13th. Citigroup boosted their target price on shares of Biohaven from $14.00 to $17.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Wall Street Zen cut shares of Biohaven from a “sell” rating to a “strong sell” rating in a report on Sunday, April 26th. Weiss Ratings restated a “sell (e+)” rating on shares of Biohaven in a report on Tuesday, June 2nd. Finally, HC Wainwright restated a “neutral” rating and set a $10.00 target price on shares of Biohaven in a report on Tuesday, May 26th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $22.27.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.